Uromigos-ASCO
Advertisement
Silke Gillessen joins Tom and Brian, who give their opinion on new data presented at the conference.
David McDermott discusses the adjuvant vs neoadjuvant trial and its wider implications for the genitourinary oncology field.
Dr. Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node-only first-line UC patients.
Dr. Laurence Albiges discusses this biomarker which may have predictive and prognostic capabilities for kidney cancer.
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of the KN426 and CLEAR trials.
Dr. Andrea Necchi describes the efficacy and toxicity of neoadjuvant sacituzumab govitecan in urothelial carcinoma.
Dr. Jonathan Rosenberg breaks down the data available for the bladder cohort from the DESTINY-PanTumor02 trial.
Dr. Alex Wyatt describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.
Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study for castration-resistant prostate cancer.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
Silke Gillessen, MD, PhD joins The Uromigos to discuss the genitourinary oncology highlights of ASCO 2023.
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial.
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.
We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.